io9 is proud to present fiction from LIGHTSPEED MAGAZINE. Once a month, we feature a story from Lightspeed’s current issue. This month’s selection is “The CRISPR Cookbook: A Guide to Biohacking Your ...

io9 is proud to present fiction from LIGHTSPEED MAGAZINE. Once a month, we feature a story from LIGHTSPEED’s current issue. This month’s selection is “The CRISPR Cookbook (Chapter Two): A Guide to ...

Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving ...

Turning genes on and off is like flipping a light switch, controlling whether genes in a cell are active. When a gene is turned on, the production of proteins or other substances is promoted; when ...

Vertex and CRISPR Therapeutics have submitted their CRISPR-based ex vivo cell therapy exagamglogene autotemcel (exa-cel) for FDA approval, for sickle cell disease (SCD) and beta-thalassemia. A ...

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

CRISPR technology may soon lead to major stock growth in genomics. CRISPR therapies target diseases with genetic editing either inside or outside the body. Beam, CRISPR Therapeutics, Caribou, and ...